CMS Announces New Oncology Payment Reform Model; Mixed Reactions from ASCO, NCCS and Others
This week in healthcare, CMS/CMMI unveils their new oncology payment reform model with strong reaction from major oncology professional organizations and a new, global patient advocacy poll reveals how patient groups really feel about drug makers around the world.
This week CMS/CMMI released its new oncology payment reform model, which the Community Oncology Alliance (COA) described as “along the lines of the COA Oncology Medical Home model with a care management fee and then a performance-based fee with quality measures.”
New CMS Oncology Care Model Relies on Broken Fee-for-service System
In this response to CMS’s release of its new oncology payment reform model, ASCO “commend[s] CMS for seeking new approaches to physician payment” and “expresse[s] concerns over the model’s limited scope.”
A recent report from the National Coalition for Cancer Survivorship stated that “many patients still experience gaps in their care and lapses in quality, and they pay a high price for the care they receive,” and outlined NCCS’s recommendations for payment reform.
An annual poll conducted by research firm PatientView surveyed 1,150 patient groups in 58 countries over the last few months to discover which companies ranked highest based on “integrity; transparency; providing needed information; emphasizing product safety and selling needed drugs.” The results? HIV medicine maker ViiV Healthcare won out four of the six categories, and the overall view of generic drug makers ranked at 40% saying they had an “excellent” or “good” reputation, compared to 39% for brand name drug makers.
Meaningful use penalties: CMS releases physician reimbursement reduction details, latest attestation numbers
In the quest for electronic health record (EHR) meaningful use attestation, recently CMS said that “more than three-quarters of eligible professionals (EPs) so far have not attested to any stage of the meaningful use program.” They also noted that “Of the 256,000 eligible professionals (EPs) who are being penalized for failing to attest, 34% (or 87,000) providers will be penalized $250 or less, 21% (55,000) will forfeit between $250 and $1,000, 14% will be penalized between $1,000 to $2,000, and 31% will lose $2,000 or more this year.”
In this article published in the ASCO Post, Thomas Gallo of the Virginia Cancer Institute shared his thoughts about shifting to more of a value focus in cancer care: “Whether the care is delivered in a cancer center or a community practice, having the infrastructure in place to collect data is paramount to driving success with the various value-based programs that are emerging.”
Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.